odronextamab
Sponsor Regeneron Pharmaceuticals, INC. · listed as REGN
odronextamab is a drug asset sponsored by Regeneron Pharmaceuticals, INC., listed as REGN. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Feb 7, 2028 (day precision, medium confidence), tied to trial NCT06091254. That trial is in Phase 3 and currently recruiting, studying Follicular Lymphoma (FL). It appears across 6 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for odronextamab in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT06091254 catalyst | Phase 3 | Recruiting | 2028-02-07 | Experimental | Regeneron Pharmaceuticals | Follicular Lymphoma (FL) |
| NCT06091865 | Phase 3 | Recruiting | 2028-03-30 | Experimental | Regeneron Pharmaceuticals | Diffuse Large B-cell Lymphoma (DLBCL) |
| NCT06230224 | Phase 3 | Active, not recruiting | 2028-05-29 | Experimental | Regeneron Pharmaceuticals | B-Cell Non-Hodgkin Lymphoma (B-NHL) |
| NCT06097364 | Phase 3 | Active, not recruiting | 2029-07-29 | Experimental | Regeneron Pharmaceuticals | Follicular Lymphoma (FL) |
| NCT06149286 | Phase 3 | Recruiting | 2031-04-30 | Experimental | Regeneron Pharmaceuticals | Relapsed/Refractory Follicular Lymphoma; Relapsed/Refractory Marginal Zone Lymphoma (R/R M… |
| NCT05991388 | Phase 2/3 | Recruiting | 2031-05-01 | Experimental | University of Birmingham | B-cell Non Hodgkin Lymphoma |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More REGN catalysts